Authors
Latest:
Updated Screening Guidelines in Prostate CancerMaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.
Latest:
Dr. Terashima on Future of Bursectomy and Omentectomy for Gastric CancerMasanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.
Latest:
Discussion of RESORCE TrialPanelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
Latest:
Future Directions of HCCStephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).
Latest:
Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast CancerMassimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.
Latest:
Closing Remarks on Treating Patients with HR+ Breast CancerMassimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.
Latest:
Importance of Quality of Life Endpoints in Clinical TrialsMassimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.
Latest:
New Angiogenesis Inhibitor May Be Effective Against a Broad Range of CancersResearchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.
Latest:
Dr. Opyrchal on the Current State of Biomarkers in TNBCMateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.
Latest:
Dr. Mathew Hall on the Impact of PSA Screening RecommendationsMathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.
Latest:
Dr. Rummel on the Chemical Structure of BendamustineDr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure
Latest:
Decision Support Systems in Oncology: Are we there yet?The push for clinical decision support technology in medicine is a logical consequence of our experiences as consumers and the need for intelligent support at the bedside.
Latest:
Understanding the Implications of Mandatory Vendor Imposition in OncologyThe rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.
Latest:
Strong Evidence for Palliative Care Intervention But Adoption Is SlowAs more studies link aggressive end-of-life oncology care to problems such as suboptimal cost and quality outcomes, experts are increasingly proposing earlier, more comprehensive palliative care interventions.
Latest:
Breast Cancer Management: Future Directions in Fertility PreservationClosing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.
Latest:
Dr. Gubens Discusses the Role of PD-L1 in Patients With NSCLCMatthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.
Latest:
Future Directions and Unmet Needs in Relapsed/Refractory MCLA panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Latest:
Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial CancerFloor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Updates on Imaging-Based Pancreatic Cancer Surveillance for Individuals With Increased Genetic and Familial RiskRecent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.
Latest:
Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian CancerMatthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Dr. Cooperberg on Using Antagonists for Hormonal Therapy in Prostate CancerMatthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the efficacy of using an antagonist with hormone therapy in prostate cancer.
Latest:
Managing Toxicities in Short- and Long-Term Treatment with ADCsVijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Latest:
Dr. Hellmann on Tumor Mutational Burden Testing in Patients With Lung CancerMatthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.
Latest:
Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLLMatthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume DelineationThe ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Latest:
Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRCMatthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).
Latest:
PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical CancerPatient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.
